Vivotif 2,000,000,000 UNT Delayed Release Oral Capsule
RxNorm 762602
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 762602 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: Vivotif 2,000,000,000 UNT Delayed Release Oral Capsule.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SBDPrescribable
Semantic Branded Drug (SBD):
Salmonella typhi Ty21a live antigen 2000000000 UNT Delayed Release Oral Capsule [Vivotif]
(Atom ID: 12361970)
PSNPrescribable
Prescribable Name (PSN):
Vivotif 2,000,000,000 UNT Delayed Release Oral Capsule
(Atom ID: 8234450)
SYPrescribable
Synonym (SY):
Vivotif 2,000,000,000 UNT Delayed Release Oral Capsule
(Atom ID: 8234451)
SYPrescribable
Synonym (SY):
Vivotif Berna 2,000,000,000 UNT Delayed Release Oral Capsule
(Atom ID: 8234452)
Patient Education
Typhoid Vaccine
What is typhoid? Typhoid (typhoid fever) is a serious disease. It is caused by bacteria called Salmonella Typhi. Typhoid causes a high fever, fatigue, weakness, stomach pains, headache, loss of appetite, and sometimes a rash. If it is not treated, it can kill up to 30% of people who get it. Some people who get typhoid become ''carriers,'' who can spread the disease to others. Generally, people get typhoid from contaminated food or water. Typhoid is rare in the U.S., and most U.S. citizens who get the disease get it while traveling. Typhoid strikes about 21 million people a year around the world and kills about 200,000.
[Learn More]
* Please review the disclaimer below.